Asthmatic Bronchitis Clinical Trial
Official title:
Difference in Gene Expression Profile in Peripheral Blood Mononuclear Cells and Inflammation Profile in Patients With Classic Asthma, Cough Variant Asthma, and Eosinophilic Bronchitis Compared With Healthy Controls
This study aims to identify and validate the gene expression differentials of peripheral blood mononuclear cells and differential inflammation profiles and other aspects in classic asthma, cough-variant asthma and eosinophilic bronchitis.
Asthma is a common and heterogeneous respiratory disorder affecting millions of people,
posing a considerable burden on health care systems globally. The disease is characterized
by inflammation of the airways with eosinophils, neutrophils, mast cells, lymphocytes,
airway epithelial cells, smooth muscle cells and other cells, by airflow obstruction and by
bronchial hyperresponsiveness. The disease is triggered by multiple gene-environment
interactions. Asthma heterogeneity is recognized in terms of clinical phenotypes of asthma
whereby classic asthma (CA) and cough variant asthma (CVA) are identified. classic asthma is
a common phenotype of asthma that presents episodic dyspnoea and wheezing with or without
cough. Cough variant asthma is a phenotype of asthma that presents solely cause of chronic
cough.
Eosinophilic bronchitis (EB) is a common cause of chronic cough, which like eosinophils
asthma is characterized by airway eosinophilic inflammation, but unlike asthma there is no
airway hyperresponsiveness or variable airflow obstruction.
Improvement of disease diagnosis and management require a better understanding of disease
heterogeneity. A useful biomarker for phenotype recognition will represent underlying
pathologic mechanisms of disease, marking heterogeneity and guiding personalized treatment
approaches. Our hypothesis was that the different clinical manifestos in patients with
eosinophilic bronchitis, classic asthma, and cough-variant asthma could be caused by
differential gene expression profiles of peripheral blood mononuclear cells (PBMC) and
differential inflammation profiles and other aspects.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03199976 -
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
|
Phase 4 |